Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •\[Phase 1 study (DLT evaluation)\]
• •Patients who underwent any major surgical treatment within 4 weeks prior to the initiation of the investigational product.
• •Patients with poorly controlled diseases. The followings are the examples but the diseases will not be limited to those.
• •Patients in whom any of HBV antigen/antibody, HCV antibody, HIV antibody or HTLV-1 antibody will be positive at screening test.
• •Patients with active interstitial lung disease or a history thereof.
• •Patients who have received the investigational products other than ME-401, systemic chemotherapy or radiotherapy within 4 weeks prior to the initiation of ME-401.